Abstract:Topical squaric dibutylester (SADBE) is currently used in Europe to treat alopecia areata In adults. We attempted to determine this drug's effectiveness and convenience in treating children with severe aiopecia areata who are psychologically disturbed and resistant to other therapies. Twenty‐eight children under 13 years of age who had extensive and Song‐standing alopecia areata and were not responsive to conventional therapies were sensitized on the head with 2 SADBE in acetone and treated with weekly applications for 12 months. Nine patients (32.1) achieved complete or cosmeticaliy acceptable regrowth, and another six (21.4) had significant regrowth. No correlation was found between response and sex, age of onset of illness, extent, duration, or clinical type of disease. In 14 patients followed for a period ranging from 18 months to 8 years SADBE remained efficacious for reiapses as weSi. This study demonstrates that SADBE is a valid and suitable treatment for children, particuiarly those who are resistant to conventional therap
展开▼
